会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES
    • 5,6,7,8-四氢-1H-咪唑并〔1,5-A〕吡嗪衍生物
    • WO2008078291A1
    • 2008-07-03
    • PCT/IB2007/055245
    • 2007-12-20
    • ACTELION PHARMACEUTICALS LTDAISSAOUI, HamedBOSS, ChristophGUDE, MarkusKOBERSTEIN, RalfSIFFERLEN, Thierry
    • AISSAOUI, HamedBOSS, ChristophGUDE, MarkusKOBERSTEIN, RalfSIFFERLEN, Thierry
    • C07D487/04
    • C07D487/04
    • The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH 2 or O; R 1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R 2 represents (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 2-4 )alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR 5 R 6 or cyclopropyl; R 3 represents (C 1-4 )alkyl, (C 1-4 )alkoxy-methyl or halogen; R 4 represents (C 1-4 )alkyl; R 5 represents hydrogen or (C 1-4 )alkyl; and R 6 represents hydrogen or (C 1-4 )alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    • 本发明涉及式(I)的5,6,7,8-四氢 - 咪唑并[1,5-a]吡嗪衍生物,其中X代表CH 2或O; R 1表示苯基,该基团独立地是单 - ,二 - 或三 - 取代的,其中取代基独立地选自(C 1-4) 烷基,(C 1-4 - )烷氧基,卤素,氰基,三氟甲氧基和三氟甲基; R 2是(C 1-4)烷基,(C 1-4)烷氧基,(C 2-4)烷基, 或者环丙基;(C 1 -C 6)烷基,卤素,氰基,羟甲基,三氟甲基,C(O)NR 5 R 6或环丙基; R 3表示(C 1-4烷基)烷基,(C 1-4烷基)烷氧基 - 甲基或卤素; R 4表示(C 1-4烷基)烷基; R 5表示氢或(C 1-4烷基)烷基; 和R 6表示氢或(C 1-4烷基)烷基。 本发明还涉及这些化合物的药学上可接受的盐; 以及使用这些化合物作为药物; 特别是作为食欲素受体拮抗剂。